Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $466.79 +3.36%
Revenue Growth %: +8.4%
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +8.4%
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.37, $0.08 better than the analyst estimate of $3.29. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2 billion.
GUIDANCE:
Vertex Pharma sees FY2022 revenue of $8.4-8.6 billion, versus the consensus of $8.22 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
